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Abstract
Objective To examine the association between CD4
counts, HPV infection and the risk of cervical neoplasia
among HIV-seropositive women.
Methods A cross-sectional observational study was
conducted among 1,010 HIV-seropositive women using
cytology-based Pap smears. HPV DNA testing using Lin-
ear Array genotyping assay (Roche) was carried out in a
subset of 191 patients. Multivariable-adjusted prevalence
ratios (mPR) and 95% conﬁdence intervals (CIs) were
estimated with log-binomial regression.
Results Among 1,010 HIV-seropositive women, the
prevalence of AGC/ASCUS, LSIL and HSIL or greater was
8.3, 23.5 and 18.0%, respectively. The risk of cervical
lesions was higher with CD4\200 cells/mm
3 vs. CD4
levels[ 500/mm
3. HPV types 16 (41.7%) and HPV 56
(22.2%) were the most common types in HSIL cases.
Women with CD4 levels\200/mm
3 had a higher preva-
lence of HPV types 16 (p\0.01) and 66 (p = 0.04). No
statisticalrelationshipbetweencervicallesionsandHAART
use was found.
Conclusion The burden of HPV infection and HSIL was
high and correlated with HIV-induced immunosuppression.
HPV 16 was the most common type in HSIL and increased
in prevalence with greater immune suppression. Prophy-
lactic HPV 16 vaccination could prevent approximately
40% of HSIL cases. Strengthening screening programs is
imperative in this population.
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Cervical cancer is the second most common female cancer
worldwide, and the most common cancer among women in
many less developed countries without adequate access to
quality screening programs [1]. Oncogenic human papil-
lomavirus (HPV) is a necessary cause of invasive cervical
cancer (ICC) [2, 3], with HPV types 16 and 18 being
attributable causes in *70% of cases [4]. Although most
HPV infections are cleared within 6 months to 2 years [5],
persistence of HPV infection is consistently associated
with an increased risk of high-grade cervical neoplasia and
ICC [6].
Globally in 2007, an estimated 33.2 million people were
HIV infected; 22.5 million of these people live in sub-
Saharan Africa with 61% (13.75 million) of these being
women [7]. HIV-seropositive women have a notably higher
risk of cervical neoplasia and ICC than HIV-seronegative
women [8]. HIV-induced immunosuppression has been
associated with a higher risk of cervical neoplasia and a
higher prevalence of overall and oncogenic type HPV
infections [9]. Among HIV-seropositive women, HPV
infections are not only more common [10, 11], but are
more likely to persist [12, 13] and consequently result in a
higher prevalence of high-grade cervical lesions [14, 15]
than among HIV-seronegative women.
Data concerning the relative importance of the most
common HPV types in ICC among HIV-seronegative
women (type 16) have been inconsistent among HIV-
seropositive women [4, 16] and [17]. These data have
important implications for currently available HPV pro-
phylactic vaccines targeting oncogenic HPV types 16 and
18 [18, 19]. A global review of HPV types in HIV-
seropositive women found that HPV type 16 prevalence
increased with increasing severity of cervical lesions [17],
but was less commonly found in high-grade squamous
intra-epithelial lesions (HSIL) cases in HIV-seropositive
women when compared to HSIL among HIV-seronegative
women [4, 17]. In contrast, a case-series from Kenya found
a similar proportion of HPV 16 positive among HIV-
seropositive (41%) than HIV-seronegative women (44%)
with ICC [8]. Among HIV-seropositive women from North
America and Europe, HPV 16 prevalence was more weakly
associated with immune suppression (as measured by
reduced CD4 counts) than other HPV types [9, 20], sug-
gesting that HPV 16 may be better able to evade immune
responses than other HPV types. Data are currently lacking,
however, on associations between HIV-induced immune
suppression and type-speciﬁc HPV 16 infection among
HIV-seropositive women within the African context.
With the global increase in funding to facilitate the
treatment of more HIV-infected individuals in less devel-
oped countries, more HIV-infected women are now
accessing antiretroviral therapy. Some previous studies
have shown a regression of cervical lesions among HIV-
infected women receiving highly active antiretroviral
therapy (HAART) [21, 22]; however, others have shown no
difference between women untreated or treated with dif-
ferent antiretroviral regimens [14, 23]. One study found
that HAART therapy did not appear to signiﬁcantly affect
oncogenic HPV persistence [24], and cervical HPV infec-
tion has been shown to persist in a high proportion of
patients using HAART [21, 23]. Although HAART for
HIV-infected women has a clear effect on restoration of the
immune status, the effect of antiretroviral treatment on
cervical neoplasia is little known and still debated.
We present here an observational study examining HIV-
induced immune suppression (measured by reduced CD4
counts) and other factors on the risk of HPV infection and
cervical neoplasia among HIV-seropositive women in
South Africa.
Materials and methods
Study population and enrollment
A baseline, cross-sectional study of HIV-infected women
was conducted within the South Africa Cervical Cancer
Cohort (SACCC) [25]. HIV-infected women aged from 18
to 65 were recruited from an adult HIV outpatient clinic in
a teaching hospital afﬁliated with the University of Wit-
watersrand in Johannesburg. Women were eligible to par-
ticipate in this study unless they (1) were pregnant; (2) had
undergone a hysterectomy or conization; (3) were severely
ill; or (4) had symptoms and/or signs suggestive of a sex-
ually transmitted infection (STI). Women were study eli-
gible following the treatment of any symptomatic STI, and,
if pregnant, 6 weeks after delivery. Of 1,574 women who
met eligibility criteria, 66% agreed to join the study,
resulting in 1,039 participating women. After the exclusion
of 29 women with cytological data not available, a total of
1,010 HIV-infected women were included.
After an educational session was presented on cervical
cancer screening inEnglishorZulu,womenwere invitedfor
a Pap smear and to participate in this observational study.
Health workers screened for exclusion criteria, explained
study aims and obtained written informed consent. A med-
ical history was obtained by participant interview including
information on sociodemographics, antiretroviral therapy
status and lifestyle factors, including smoking/snuff (tradi-
tional chewing tobacco), reproductive/menstrual character-
istics, previous Pap smear results if applicable, sexual
history/behaviors, history of STIs and contraceptive use. All
protocols were reviewed and cleared by the Ethical Com-
mittee of the University of Witwatersrand Human Research
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123Ethics Committee (Medical) and, for secondary data anal-
ysis, from the University of North Carolina.
Gynecological examination, specimen collection
and processing
During a pelvic examination, cervical exfoliated cells were
collected using two individual endocervical brushes for a
conventional Pap smear diagnosis and HPV DNA detec-
tion. Conventional cervical smears were performed as
liquid-based cytology is currently not available in South
Africa. Cytology slides were read and analyzed according
to the Bethesda 2001 reporting guidelines [26]. Women
with atypical squamous cell-high (ASC-H) and HSIL were
referred for immediate colposcopy. Women with ASCUS
or low-grade intra-epithelial lesions (LSIL) were followed
with a repeat Pap smear after 1 year if their CD4 count
was C 200, or after 6 months if their CD4 count was\200/
mm
3. Women were also referred for colposcopy if there
were 3 consecutive LSIL results over 18 months or greater.
For quality control, 10% of the conventional cytology
slides were sent to University of North Carolina for blinded
double-reading on two occasions, and a high rate of con-
cordance was observed (81–85%). HPV brushes were
placed in PBS solution and stored in a 4C refrigerator and
shipped to University of Cape Town on ice for HPV DNA
laboratory testing within 2 weeks of collection.
HIV-seropositive women were treated according to the
HIV South African Guidelines on Comprehensive HIV and
AIDS Care, Management and Treatment [27], which ini-
tiates highly active antiretroviral therapy (HAART) at
WHO stage 4 or CD4 count B 200 cells/mm
3. The women
who had CD4 counts over 500 had originally started HA-
ART according to the above criteria and had good clinical
response to treatment.
HPV DNA PCR laboratory testing
HPV DNA testing was conducted on samples from ran-
domly selected women using the Roche Linear Array HPV
genotyping test (Roche Molecular Systems Inc. California
USA), and the results were validated utilizing the beta-
globin according to the manufacturer’s instructions. Lab-
oratory personnel were blinded of all other laboratory and
medical history data. HPV DNA results were limited to 191
women (*20% of the study population) due to funding
constraints.
The Pap smear was done at the same visit that the HPV
DNA was collected from women without any knowledge of
any previous Pap smear results, and the woman chosen
were the ﬁrst 191 women who agreed to have the HPV
testing done. The Linear Array assay detects a total of 37
HPV types. Individual HPV types were divided into 14
oncogenic (high risk) types: 16, 18, 31, 33, 35, 39, 45,51,
52, 56, 58, 59, 66, 68, and 23 non-oncogenic types (low
risk): HPV 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67,
69,70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108 [28].
Statistical analysis
Current antiretroviral therapy status, sociodemographic,
reproductive and sexual behavior characteristics were cal-
culated, stratiﬁed by three CD4 count categories (\200,
200–500 and [500/mm
3). Age-adjusted prevalence ratios
(PRs) for cervical lesions and corresponding 95% conﬁ-
dence intervals (CIs) were calculated by means of log-
binomial regression [29] for each grade of cervical
abnormality according to the Bethesda classiﬁcation sys-
tem [26] (ASCUS, LSIL, and HSIL or greater). Multivar-
iable-adjusted prevalence ratios (mPR) and 95% CIs were
estimated with log-binomial regression to determine fac-
tors associated with cervical lesion outcomes. An initial
multivariable model included all potential confounders,
and ﬁnal multivariable model was built using a backward
selection method with 10% change-in-estimate criteria. We
systematically choose to retain variables in the ﬁnal mul-
tivariable model if they were signiﬁcant for any clinical
outcome (AGC/ASCUS, LSIL, C HSIL) in order to allow
the direct comparison of risk factors between different
stages of cervical neoplasia. Multivariable models included
age categorized into three levels: \30, 30–40 and
[40 years. Polychotomous variables were included as sets
of indicator variables.
The number and relative percentage of HPV types were
calculated among a subgroup of 191 women with available
data on HPV DNA, stratiﬁed by cervical status and CD4
count grouping. The prevalence of overall HPV, multiple
and single oncogenic HPV types was also calculated.
Women in the oncogenic group have at least one or more
oncogenic types. Relative differences in HPV prevalence
were tested using chi-squared statistics using two-sided
p values and were not adjusted for other risk factors.
Results
A total of 1,010 HIV-seropositive women participated,
with a median age 34 years (range 18–65). Approximately
one-third of women (32.4%) reported having graduated
from high school. Few women reported ever smoking
(5.5%) and 20.8% reported current alcohol use. A high
proportion of women (42.8%) reported having had ﬁve or
more lifetime sexual partners. The most commonly repor-
ted method of contraception was male condoms (75.4%),
while 12.4% reported a history of oral contraceptive use.
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123Over two-thirds (72%) of women reported having never
had a Pap smear. Less than 1% of women reported a pre-
vious history of treatment of cervical dysplasia.
When examining differences by stratiﬁed CD4 counts
(Table 1), more women with lower CD4 counts\200/
mm
3 were currently on antiretroviral (HAART) therapy
(74.5%) than with higher CD4 counts[500/mm
3 (51.7%)
(p\0.01). Women with CD4 counts\200/mm
3 were
also less likely to report current use of oral contraceptives
compared to women with CD4 counts[500/mm
3 (9.6 vs.
11.9%, p\0.05) (Table 1). Other factors did not appear
to be associated with HIV-induced immune suppression,
including educational attainment, smoking, alcohol status,
age at ﬁrst intercourse, history of condom use or reported
number of sexual partners.
Cervical lesions and other characteristics
The overall prevalence of ASCUS/AGC (atypical glandular
cells), LSIL, HSIL or greater was 8.3, 23.5 and 18.0%,
respectively. A total of 2 cases of ICC were found, resulting
in a prevalence rate of 198/100,000. Lower CD4 count
levels after adjusting for age were associated with an
increasedprevalenceofabnormalcervicalcytology.Onlyin
the ASCUS/AGC category this trend was not found to be
statistically signiﬁcant: ASCUS/AGC (including 2 cases of
AGC): (PR = 1.9; 95% CI: 0.9–3.7 for CD4\200/mm
3
vs. [500/mm
3), LSIL (PR = 2.5; 95% CI: 1.6–4.0 for
CD4\200/mm
3 vs.[500/mm
3 and HSIL (PR = 2.5; 95%
CI: 1.5–4.4 for CD4\200/mm
3 vs.[500/mm
3)(Table 2).
When compared to women under 30 years of age, LSIL was
Table 1 Sociodemographic, sexual behavior and reproductive characteristics of 1,010 HIV-infected women in Johannesburg, South Africa
CD4\200/mm
3 CD4 200–500/mm
3 CD4[500/mm
3 Overall
n 428 464 118 1,010
Age (median in years, range) 34 (20–57) 34 (18–65) 34 (19–56) 34 (18–65)
CD4 count/mm
3 (median, range) 102 (1–199) 304 (200–499) 626 (501–1,789) 231 (1–1,789)
HAART
a (%) (p for difference\0.001)
None 25.5 40.5 48.3 35.1
Regime 1a
b 61.7 37.7 22.9 46.1
Regime 1b
b 8.4 8.4 10.2 8.6
Regime 2
b 1.4 3.5 5.1 2.8
Others 3.0 9.9 13.6 7.4
Cervical status (%) (p for difference\0.001)
Normal 39.5 55.6 67.8 50.2
AGC
c/ASCUS 9.1 7.8 7.6 8.3
LSIL 31.8 18.1 14.4 23.5
CHSIL
d 19.6 18.5 10.7 18.0
Education (%)
Up to grade 8 30.4 24.1 24.6 26.8
Grade 8–12 39.3 43.5 35.6 40.8
C12 30.4 32.3 39.8 32.4
Ever smoking (%) 4.2 7.1 4.2 5.5
Current alcohol use (%) 18.0 23.3 21.2 20.8
Age at ﬁrst intercourse (%)
\15 years 11.5 11.2 9.3 11.1
15–18 years 58.4 55.8 55.9 56.9
C19 years 30.1 33.0 34.8 32.0
Number of lifetime sexual partners C 5( %
e) 45.0 42.6 35.6 42.8
Parity (median, range) 2 (0–9) 2 (0–7) 2 (0–7) 2 (0–15)
Current oral contraceptive use (%) (p for difference\0.05) 9.6 15.1 11.9 12.4
Current condom use (%) 80.0 76.9 81.4 75.4
a HAART—highly active antiretroviral therapy
b 1a Stavudine, Lamivudine, Efavirenz; 1b Stavudine, Lamivudine, Nevirapine; 2 Zidovudine, Didanosine, Lopinavir/Ritonavir
c AGC/ASCUS include 2 cases of AGC
d CHSIL includes 2 cases of ICC
e Denominators for percentages excluded observations with missing values
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123also less prevalent among women 30–40 years of age
(PR = 0.8; 95% CI: 0.6–0.9) and women over 40
(PR = 0.6; 95% CI: 0.4–0.8). Both ASCUS and HSIL
were also less likely among women over age 40, although
associations were not statistically signiﬁcant (Table 2).
Approximately, one-third of women with LSIL (31.2%,
74/237) and one-ﬁfth of women with HSIL (20.9%, 38/182)
were 30 years or younger.
Current alcohol use was associated with slightly higher
prevalence of HSIL (age-adjusted PR = 1.2; 95% CI: 1.1–
1.3) (Table 2). Age-adjusted prevalence of abnormal cer-
vical cytology was not signiﬁcantly associated with the
sexual history such as age at ﬁrst intercourse, number of
life time sexual partners and higher parity. However,
abnormal cytology prevalence appeared to be lower for
women who reported current condom use vs. non-users for
Table 2 Risk factors and prevalence ratios among 1,010 HIV-infected women in Johannesburg, South Africa
Normal AGC/ASCUS
a LSIL CHSIL
b
n = 507 n = 84 PR
c (95% CI) n = 237 PR
c (95% CI) n = 182 PR
c (95% CI)
Age (years)
\30
d 106 27 1 74 1 38 1
30–40 267 40 0.6 (0.4–1.0) 120 0.8 (0.6–0.9) 103 1.1 (0.8–1.5)
[40 134 17 0.6 (0.3–1.0) 43 0.6 (0.4–0.8) 41 0.9 (0.6–1.3)
CD4 count/mm
3
\200 169 39 1.9 (0.9–3.7) 136 2.5 (1.6–4.0) 84 2.5 (1.5–4.4)
200–500 258 36 1.2 (0.6–2.5) 84 1.4 (0.9–2.3) 86 1.9 (1.1–3.3)
[500
d 80 9 1 17 1 12 1
p for trend\0.01 p for trend\0.001 p for trend\0.001
Education attainment (grade)
\8
d 147 22 1 54 1 48 1
8–12 198 31 1.0 (0.9–1.1) 102 0.9 (0.8–1.1) 81 0.9 (0.9–1.1)
[12 162 31 1.0 (0.9–1.1) 81 1.0 (0.8–1.1) 53 1.0 (0.9–1.1)
Current alcohol use
No
d 393 61 1 187 1 159 1
Yes 114 23 1.0 (0.9–1.1) 50 1.0 (0.9–1.1) 23 1.2 (1.1–1.3)
Age at ﬁrst intercourse (years)
C19
d 180 21 1 71 1 51 1
15–18 267 52 1.6 (1.0–2.6) 146 1.2 (1.0–1.6) 110 1.3 (1.0–1.8)
\15 60 11 1.4 (0.7–2.8) 20 0.8 (0.5–1.3) 21 1.1 (0.7–1.8)
Number of lifetime sexual partners
e
\5
d 281 40 1 140 1 114 1
C5 221 44 1.4 (0.9–2.0) 97 0.9 (0.8–1.2) 68 0.8 (0.6–1.1)
Parity
0 78 13 1.0 (0.6–1.9) 30 1.0 (0.6–1.1) 13 0.6 (0.3–1.0)
1
d 164 24 1 84 1 51 1
C2 265 47 1.4 (0.8–2.2) 123 1.0 (0.8–1.3) 118 1.4 (1.0–1.8)
Current oral contraceptive use
No
d 442 72 1 216 1 155 1
Yes 65 12 1.0 (0.9–1.1) 21 1.1 (1.0–1.3) 27 1.0 (0.8–1.1)
Current condom use
No
d 117 20 1 54 1 58 1
Yes 390 64 0.9 (0.5–1.4) 183 0.9 (0.7–1.2) 124 0.7 (0.5–0.9)
a AGC/ASCUS include 2 cases of AGC
b CHSIL includes 2 cases of ICC
c Age-adjusted prevalence ratio (PR) vs. 507 HIV-seropositive women with normal cervical status
d Reference category
e Denominators for percentages exclude observations with missing values
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123HSIL cases (PR = 0.7; 95% CI: 0.5–0.9 for HSIL
(Table 2). A history of smoking, using snuff or current oral
contraceptive use did not show any association with
abnormal cervical cytology (Table 1).
In the multiple log-binomial regression models, lower
CD4 count (\200 vs. [500/mm
3) was consistently asso-
ciated with all grades of cervical neoplasia: HSIL
(mPR = 2.4; 95% CI: 1.4–4.2), LSIL (mPR = 2.4; 95%
CI: 1.5–3.8) and ASCUS (mPR = 1.8; 95% CI: 0.9–3.6)
(Table 3). Associations between current HAART use were
not statistically signiﬁcant in the multivariate model
(mPR = 1.3; 95% CI: 0.9–1.7 for HSIL; mPR = 1.2; 95%
CI: 0.9–1.5 for LSIL; PR = 1.3; 95% CI: 0.8–1.9 for
ASCUS).
Associations between HPV infection, cervical lesions
and CD4 count
Among the 191 women with HPV DNA results, the prev-
alence and distribution of abnormal lesions were the same
as the main cohort: AGC/ASCUS 7.3% (14/191), LSIL
27% (52/191) and HSIL 18.3% (35/191). There was no
statistical difference between the subgroup of women with
HPV typing and the main cohort in terms of age, CD4
count, HAART use, educational level, age of ﬁrst sexual
encounter, number of lifetime sexual partners, condom use
or smoking habits.
There was a higher prevalence of overall (p\0.01),
single (p\0.01) and multiple oncogenic HPV types
(p\0.01) with increasing grade of cervical abnormalities.
The prevalence of HPV 16 (p\0.01), 56 (p\0.01), HPV
33 (p = 0.03), HPV 59 (p = 0.06) and HPV 66 (p = 0.01)
was also higher in HIV-seropositive women with HSIL or
LSIL compared to those with HIV-seropositive women
with normal or ASCUS diagnoses (Fig. 1). Compared to
women with normal cervical cytology, women with LSIL,
HSIL or AGUS/ASCUS had a higher prevalence of any
HPV positivity (HSIL: 88.9%, LSIL: 98.0%, AGUS/
ASCUS: 100% and normal: 74.4%, p\0.01), any onco-
genic HPV (HSIL: 77.8%, LSIL: 90.2%, AGUS/ASC 71%,
normal: 60.0%, p\0.01) or multiple oncogenic HPV
types (HSIL: 58.3%, LSIL 68.6%, AGUS/ASC 42.9%
normal: 38.9%, p\0.01). The prevalence of oncogenic
and multiple HPV types appeared to be generally similar in
LSIL and HSIL cases. However, the absolute number of
HPV types found in LSIL appeared to be higher in that in
HSIL cases (Fig. 2).
HPV type 16 appeared to be more prevalent in more
advanced cervical dysplasia (HSIL: 41.7%, 95% CI: 24.8–
58.6% (15/36 women), LSIL: 37.3%, 95% CI: 23.5–51.0%,
(19/51 women), ASCUS: 14.3%, 95% CI: 0.0–35.3% (2/14
women) and normal: 17.8%, 95% CI: 9.7–25.8% (16/90
women) (p = 0.002). In women with negative cytology
results, a signiﬁcant association was seen between CD4
count and HPV 16 with CD4\200: 27.3% (9/33), 200–
500: 15.2% (7/46) and [500: 0% (0/11), p = 0.03. HPV
type 18 was relatively less common in HSIL (2.8%, 95%
CI: 0.0–8.4%). No signiﬁcant difference in HPV positivity
by grade of cervical lesion was found for any other indi-
vidual HPV type. The most common oncogenic HPV types
Table 3 Risk factors and multivariate prevalence ratios among 1,010 HIV-infected women in Johannesburg, South Africa
Normal AGC
a/ASCUS LSIL CHSIL
b
n = 507 n = 84 mPR
c (95% CI) n = 237 mPR
c (95% CI) n = 182 mPR
c (95% CI)
Age
\30 years
d 106 27 1 74 1 38 1
30–40 years 267 40 0.7 (0.4–1.0) 120 0.8 (0.6–0.9) 103 1.0 (0.7–1.4)
[40 years 134 17 0.5 (0.3–1.0) 43 0.6 (0.4–0.8) 41 0.8 (0.6–1.2)
CD4 count/mm
3
\200 169 39 1.8 (0.9–3.6) 136 2.4 (1.5–3.8) 84 2.4 (1.4–4.2)
200–500 258 36 1.2 (0.6–2.4) 84 1.4 (0.9–2.2) 86 1.9 (1.1–3.3)
[500
d 80 9 1 17 1 12 1
HAART
e
No
d 201 27 1 71 1 55 1
Yes 306 57 1.3 (0.8–1.9) 166 1.2 (0.9–1.5) 127 1.3 (0.9–1.7)
a AGC/ASCUS include 2 cases of AGC
b CHSIL includes 2 cases of ICC
c Multivariate prevalence ratio (mPR) adjusted for all variables listed in the table vs. 507 HIV-seropositive women with normal cervical status
d Reference category
e HAART—highly active antiretroviral therapy: 1a Stavudine, Lamivudine, Efavirenz; 1b Stavudine, Lamivudine, Nevirapine; 2 Zidovudine,
Didanosine, Lopinavir/Ritonavir
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123found in women with HSIL lesions or greater were HPV
type 16 (41.7%), HPV 56 (22.2%), HPV type 66 (16.7%),
HPV type 33 (13.9%) and HPV type 59 (11.1%), whereas
in LSIL, the most common types included HPV types 16
and 18 (each at 35.3%), HPV 56 and 66 (each at 19.6%)
and 61 (23.5%). Combined prevalence of HPV 16 and/or
18 were 41.7% for HSIL, 52.9% for LSIL, 28.9% for
women with normal diagnoses (p = 0.02).
HIV-seropositive women with CD4 levels\200/mm
3
had higher prevalence of overall HPV types {92.0% (80/
87) vs. 64.7% (11/17) for[500 cells/mm
3, p\0.01}, any
oncogenic HPV type {81.6% (71/87) vs. 41.2% (7/17)} for
CD4 counts[500 cells/mm
3, p\0.01 and multiple
oncogenic HPV types {59.8% (52/87) vs. 35.3% (6/17),
p\0.01}. The prevalence of HPV type 16 was also more
common among women with lower CD4 counts {37.9%
(33/87) for \200/mm
3 vs. 5.9% (1/17) for [500/mm
3,
p\0.01}, as well as HPV type 66 {18.4% (16/87) vs.
11.8% (2/17), p = 0.04}.
Discussion
This cervical cancer study in Johannesburg, South Africa
is, to our knowledge, the largest to date among HIV-
seropositive women in Africa. Half of 1,010 HIV-
seropositve women had cervical lesions, with cervical
abnormalities prevalence increasing with lower CD4
immune status. High observed prevalence of ASCUS or
greater is similar to that observed in 397 HIV-seropositive
women from Cape Town, South Africa (54%) [30], yet
somewhat lower than among 150 HIV-seropositive women
from Zambia (76%) [30]. Overall observed prevalence of
LSIL (24%) and HSIL (18%) was also higher than among
0%
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123HIV-seropositive women in the United States (15.4 and
7.9%, respectively), a European cohort (21.0 and 2.8%,
respectively) [32, 33] or Zimbabwe (9.7 and 3.4%) [34].
In this study from Johannesburg, 42% of HIV-seroposi-
tive women had CD4 counts\200 cells/mm
3. Our results
of HSIL prevalence of 18% are not as high as that observed
in Zambia (33%) among a smaller number of HIV-
seropositive women who also had low median CD4 counts
of 165/mm
3,[ 31]. Observed prevalence, however, was
higher than among women with unknown HIV serostatus
screened in the Free State province, South Africa (LSIL of
18% and HSIL of 8%) [35]. The high prevalence of cervical
neoplasia in our study could be partially explained by more
advanced stages of HIV immunosuppression among female
participants when compared to previous studies from the
United States and Europe [32, 33]. In addition, the lack of
cervical cancer screening is also a likely cause of this phe-
nomenon since cervical cancer in non-HIV-infected women
is higher in South Africa than the United States. Of note,
one-ﬁfth of HSIL cases were 30 years of age or younger.
Given these results, cervical cancer screening should be
considered in HIV-seropositive women upon diagnosis
rather than being delayed until 30 years of age [36].
The number of different types of any HPV or oncogenic
HPV DNA types among HIV-seropositive women was
smaller with increasing severity of cervical neoplasia (i.e.
HIV-seropositive women with HSIL appear to have fewer
HPV types than those with LSIL). These ﬁndings are
consistent with data among largely HIV-seronegative
women [4, 17], indicative of the relatively fewer number of
HPV types that may be etiologically important for the
development of HSIL vs. lower grades of cervical neo-
plasia in HIV-seropositive women. Our results, however,
are limited to HPV DNA detection within cervical exfoli-
ated cells, rather than biopsy specimens. Although cyto-
logical results were presented in current analyses, as used
in current clinical practice, histological conﬁrmation of
study outcomes may have lead to the reclassiﬁcation of
some clinical endpoints. Of the 182 cases of HSIL or
greater, 83 had available pathology results. Most HSIL
cases were histologically conﬁrmed as CIN-2 (30%) or
CIN-3 (47%), whereas slightly less than one quarter (23%)
were classiﬁed as CIN-1 by histology. Measures of asso-
ciation between risk factors and grades of cervical neo-
plasia presented, respectively, in Tables 2 and 3, were
similar, however, when CIN, rather than SIL, classiﬁca-
tions were used.
HPV 16 was the most common HPV type in HIV-
seropositivewomenwithHSIL(41.7%)inthepresentstudy,
with HPV 18 being relatively rare (2.8%). These results are
similar to a review of African data among largely HIV-
seronegative women where HPV 16 and/or 18 prevalence
was 45% in HSIL [4], Among 77 HIV-seropositive women
with HSIL from Zambia [31], HPV 52 was the most com-
mon type, followed by HPV types 58. A previous review
indicated that HSIL cases among HIV-seropositive women
may have a lower proportion of HPV-16 positivity than
HIV-seronegative HSIL cases [17]. Given recent data from
Kenya indicating that HPV 16 prevalence was similar in
HIV-seropositive and HIV-seronegative ICC cases [8],
further data on HPV oncogenic types in HSIL and ICC cases
are needed among a larger number of HIV-seropositive
HSIL and ICC cases from Africa.
Combined HPV 16 and/or 18 prevalence among HIV-
seropositive women in South Africa was 42% HSIL and
53% in LSIL, respectively. Thus, as with HIV-seronegative
women, a notable proportion of HSIL and LSIL cases in
HIV-seropositive women could be potentially prevented by
the vaccination of female adolescents prior to ﬁrst sexual
intercourse. Not withstanding, a non-negligible proportion
of HSIL and LSIL cases will not be prevented by HPV
prophylactic vaccination, highlighting that cervical cancer
screening remains paramount for optimal cervical cancer
prevention. Further, approximately half of HSIL cases
among HIV-seropositive women in this study harbored
other high-risk HPV types 33, 56 and 66 (*47%). This is
important to consider for the development of future ther-
apeutic vaccines that are urgently needed in regions with a
high burden of ICC.
Among HIV-seropositive women from Johannesburg,
lower CD4 counts were consistently associated with a
higher risk of cervical lesions (ASCUS, LSIL and HSIL or
greater). Our results are consistent with previous screening
studies of HIV-seropositive women [37, 38]. It is not sur-
prising that HIV-seropositive women with greater immu-
nosuppression are at a higher risk of cervical disease.
Consistently, lower CD4 counts (\500 cells/mm
3) have
been associated with a higher probability of progression to
higher cervical disease grades [32, 37].
The relatively broader distribution of HPV types among
HIV-seropositive women with lower CD4 counts suggests
reactivation of latent HPV viral infections [38]. Our results
are similar to previous studies indicating that HIV-
seropositive women with CD4 counts\200/mm
3 have a
higher prevalence of any HPV or oncogenic HPV types
[11, 39, 40] when compared to those with CD4
counts[500/mm
3. Of interest, HPV 16 prevalence in our
study increased with greater immune suppression, declin-
ing from 38% among women with CD4 counts\200 cells/
mm
3 to 6% for CD4 counts[500 cells/mm
3. As a sensi-
tivity analysis, we limited analyses to HIV-seropositive
women with normal cytology and found similar results.
Albeit based on relatively smaller sample sizes, these
results suggest that within the African content that HPV 16
may not be better at evading host immune responses than
other HPV types, as previously suggested [6, 9]. Strickler
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123et al. showed a relatively weaker association of type 16
with decreasing CD4 counts than other HPV types [9]
among HIV-seropositive women from the United States
consistently, Koshiol et al. found that the persistence of
HPV 16 among HIV-seropositive women did not appear to
be associated with CD4 counts [6]. These results from
South Africa, although based on relatively small sizes,
suggest that HPV 16 prevalence may be affected by the
level of CD4 immune suppression. As previously hypoth-
esized, the relationship of HPV 16 infection with the
immune suppression in our population may differ from
European and US HIV-infected women, potentially due to
higher levels of immunosuppression in the underlying
population within the African context [9]. Further data are
needed to investigate the prevalence and persistence of
HPV 16 and other high-risk HPV types, stratiﬁed by the
level of CD4 count, in HIV-seropositive women in both
African and relatively more developed populations.
Another interesting ﬁnding in this study was that HIV-
seropositive women who used condoms had a lower risk of
HSIL than non-users (table 2): PR = 0.7 95% CI (0.5–0.9).
A study of HIV-seronegative women (n = 82) also found a
lowerriskofcervicalneoplasia amongwomenwhoreported
consistent condom use compared with those who did not
[41]. There is also evidence in HIV-seronegative women
that the consistent use of condoms was associated with a
higher clearance rate of HPV and of cervical neoplasia [42].
In our present study, a protective effect was not found with
ASCUS or LSIL with condom use.
Given the cross-sectional design, the current study can
not reliably address the temporal effect of HAART on HPV
persistence or the progression of cervical neoplasia. The
multivariate analysis did not ﬁnd any association between
HAART use and any grade of cervical neoplasia, and is in
agreement with previous research [14, 23]. One study
among 328 US women found no difference in cervical
disease prevalence between HIV-seropositive women
treated and untreated with either mono- or combination
therapy (non-HAART) over study follow-up [14]. An
Italian study of 163 HIV-seropositive women also found no
beneﬁcial effect of HAART therapy on the risk of incident
SIL, or on the progression rate of cervical lesions after
adjusting for CD4 cell count [23]. Given inconsistent
associations between HAART use and the risk of cervical
neoplasia, the effect of HAART therapy on cervical neo-
plasia is still being debated. Although potent anti-HIV
regimens are effective for the restoration of patient’s
immune system by increasing CD4 counts, limited data
suggest that HAART use may not affect HPV viral per-
sistence [21, 23]. Further prospective studies in this cohort
will be done to evaluate whether HAART has any role in
modifying the progression of cervical dysplasia in these
HIV-seropositive women. Further studies are also needed
to determine whether the earlier initiation of HAART at
higher CD4 counts than is currently recommended for
clinical practice will useful for the prevention of high-
grade cervical lesions among HIV-seropositive women.
One limitation of this study is the lack of HIV viral load
data and analysis as a measure of HIV disease status. HIV
baseline viral loads before the initiation of HAART are
generally not done in the South African government HIV
treatment clinics [27]. Another possible bias in the study is
that very ill women were excluded from the study. These
women might have had lower CD4 counts; therefore, we
may actually be underestimating the prevalence of high-
grade lesions that would have been found if these women
had not been excluded. However, we do not think that this
was a signiﬁcant selection bias, given that women with
CD4 counts\200 represents 43% of our study population.
Given that many African HIV-seropositive women are
living longer in the era of HAART, they now face longer-
term HIV-related complications including invasive cervical
cancer. The wide-spread introduction of currently available
prophylactic HPV vaccines would reduce, but not elimi-
nate, a large proportion of high-grade cervical lesions.
Thus, strengthening and expanding cervical cancer
screening program in settings where HIV prevalence is
high remains imperative.
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